Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β₂-agonist fixed-dose combination: RE²SPOND rationale and study design

Stephen I Rennard1 Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA;2 AstraZeneca, Cambridge, UKCorrespondence[email protected]

Fernando J Martinez3 Joan and Sanford I Weill Department of Medicine, Weill Cornell University, New York, NY;4 Department of Internal Medicine, Michigan Health System, Ann Arbor, MI, USA

Klaus F Rabe5 LungenClinic Grosshansdorf, Großhansdorf;6 Department of Medicine, University Kiel, Kiel;7 Airway Research Center North, German Center for Lung Research, Großhansdorf, Germany

Sanjay Sethi8 Department of Medicine, University at Buffalo, State University of New York, Buffalo, NY, USA

Emilio Pizzichini9 Department of Medicine, Universidade Federal de Santa Catarina, Santa Catarina, Brazil

Andrew McIvor10 Firestone Institute of Respiratory Health, St Joseph’s Healthcare, McMaster University, Hamilton, ON, Canada

Shahid Siddiqui11 AstraZeneca, Gaithersburg, MD

Antonio Anzueto12 South Texas Veterans Health Care System at San Antonio, University of Texas Health Science Center, San Antonio, TX

Haiyuan Zhu13 Allergan plc, Jersey City, NJ, USA

show all

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (6)

Yazdan Hasani Nourian, Jafar Salimian, Ali Ahmadi, Zahra Salehi, Mehrdad Karimi, Alireza Emamvirdizadeh, Sadegh Azimzadeh Jamalkandi & Mostafa Ghanei. (2023) cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features. Biochemistry and Biophysics Reports 34, pages 101438.
Crossref

Sadia Janjua, Rebecca Fortescue & Phillippa Poole. (2020) Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2020:5.
Crossref

Nathanael Sanchez. (2019) Roflumilast does not decrease COPD exacerbations in adequately treated patients, but subgroup analysis allows for shared decision making. Clinical Research In Practice: The Journal of Team Hippocrates 5:1.
Crossref

Fernando J. Martinez, Klaus F. Rabe, Peter M. A. Calverley, Leonardo M. Fabbri, Sanjay Sethi, Emilio Pizzichini, Andrew McIvor, Antonio Anzueto, Vijay K. T. Alagappan, Shahid Siddiqui, Colin Reisner, Sofia Zetterstrand, Jonas Román, Debasree Purkayastha, Nitin Bagul & Stephen I. Rennard. (2018) Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. American Journal of Respiratory and Critical Care Medicine 198:10, pages 1268-1278.
Crossref

Jimmy Chong, Bonnie Leung & Phillippa Poole. (2017) Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews.
Crossref

Fernando J. Martinez, Klaus F. Rabe, Sanjay Sethi, Emilio Pizzichini, Andrew McIvor, Antonio Anzueto, Vijay K. T. Alagappan, Shahid Siddiqui, Ludmyla Rekeda, Christopher J. Miller, Sofia Zetterstrand, Colin Reisner & Stephen I. Rennard. (2016) Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β 2 -Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE 2 SPOND). A Randomized Clinical Trial . American Journal of Respiratory and Critical Care Medicine 194:5, pages 559-567.
Crossref

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β₂-agonist fixed-dose combination: RE²SPOND rationale and study design

Articles from other publishers (6)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE2SPOND rationale and study design

Citations (6)

Articles from other publishers (6)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β₂-agonist fixed-dose combination: RE²SPOND rationale and study design